Non Small Cell Lung Cancer News and Research

RSS

Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011.

13 Jan 2011

Daiichi Sankyo and ArQule initiate enrollment in ARQ 197 Phase 3 trial in NSCLC

Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.

12 Jan 2011

Epigenetic therapy holds promise for cancer management

Syndax, a clinical-stage epigenetics oncology company, announced publication of data of entinostat combined with the demethylating agent Vidaza® (azacitidine) showing effect in reducing tumor burden in differentiated tumor cells in animal tumor models of non-small cell lung cancer (NSCLC). The data is being published in the January 15, 2011 issue of Cancer Research.

12 Jan 2011

Cyclacel opens enrollment of sapacitabine Phase 3 trial for AML

Cyclacel Pharmaceuticals, Inc., today announced that it has opened enrollment of the SEAMLESS pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment of elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.

11 Jan 2011

Study supports use of telomerase inhibitors for treatment of childhood cancers

Geron Corporation today announced the publication of preclinical data demonstrating that the company's telomerase inhibitor drug, imetelstat (GRN163L), currently in Phase 2 clinical trials, selectively targets cancer stem cells in pediatric tumors of neural origin.

11 Jan 2011

Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

Oncolytics Biotech Inc. announced today that a U.S. Phase I study of REOLYSIN® in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer (REO 022) is now open to enrollment. The principal investigator is Dr. Sanjay Goel of the Montefiore Medical Center at The Albert Einstein College of Medicine in New York.

10 Jan 2011

FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer

Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.

10 Jan 2011

Infinity provides guidance on anticipated pipeline and business goals for 2011

Infinity Pharmaceuticals, Inc. today provided guidance on its anticipated pipeline and business goals for 2011. Infinity begins the year with a broad pipeline of four drug candidates in clinical development and a fifth expected to enter the clinic during the year. The company also enters 2011 with approximately $345 million in committed capital.

7 Jan 2011

Antigenics announces name change to Agenus

Antigenics Inc. today announced that effective immediately it is changing its name to Agenus Inc. The company's stock will continue to be traded on NASDAQ under the symbol AGEN. The new name reflects the broadening of the company's product portfolio of clinical candidates beyond autologous antigen-based vaccines, as well as its commitment to actively pursuing licensing opportunities to leverage its development capabilities and expand its product portfolio.

6 Jan 2011

Sanofi-aventis announces publication of positive BSI-201 phase II results for breast cancer

Sanofi-aventis and its wholly-owned subsidiary, BiPar Sciences, today announced that The New England Journal of Medicine published the final phase II data for the investigational drug iniparib demonstrating significant clinical benefit in women with metastatic triple negative breast cancer when iniparib was administered in combination with chemotherapy agents gemcitabine/carboplatin.

6 Jan 2011

Isis commences ISIS-EIF4ERx Phase 2 studies in non-small cell lung cancer and prostate cancer

Isis Pharmaceuticals, Inc. announced the initiation of two Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer. These studies are part of Isis' broad Phase 2 development program designed to evaluate ISIS-EIF4ERx in multiple types of cancer. ISIS-EIF4ERx targets eukaryotic initiation factor-4E (eIF-4E), a traditionally "undruggable" target that is thought to promote tumor growth and metastasis in many cancers.

4 Jan 2011

Enrollment commences in belinostat-Tarceva combination trial for NSCLC

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, and Topotarget A/S announced today that the first patient has been dosed in an Investigator Initiated Trial of belinostat in combination with Tarceva® for patients with Non-Small Cell Lung Cancer (NSCLC).

30 Dec 2010

EMCTO 2011 to provide update on treatment of thoracic malignancies

The number of diagnostic and therapeutic options for patients with thoracic malignancies has markedly increased, allowing for an individualized approach based on the clinical situation and molecular characteristics of the tumor. How to best select among these options for the benefit of the patients within an integrative treatment approach will be at the core of the conference.

23 Dec 2010

Genentech confirms EMA, FDA updates on Avastin for metastatic breast cancer

Genentech, a member of the Roche Group, confirmed that following the reviews of Avastin® (bevacizumab) in metastatic breast cancer by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), the following regulatory announcements were made by the individual health authorities:

17 Dec 2010

Genetic breakthrough in lung cancer

For the study the team studied samples of lung tumors and nearby healthy lung tissue from 30 patients and examined the samples for the presence of messenger ribonucleic acid (mRNA) associated with 48 known genes for molecules called nuclear hormone receptors. Then they compared the active genes with patient outcomes and found that the expression of genes for certain nuclear hormone receptors helped predict patient survival.

16 Dec 2010

Combination therapy improves survival rates in patients with advanced non-small cell lung cancer

A combination therapy for treating cancer discovered at the University of Colorado Cancer Center showed improved survival rates in patients with advanced non-small cell lung cancer (NSCLC), according to results from a double-blind, placebo-controlled phase 2 trial run by Syndax Pharmaceuticals.

16 Dec 2010

Genes predict survival time, potential new treatments for patients with non-small cell lung cancer

Researchers at UT Southwestern Medical Center have discovered sets of genes active in cancer cells and normal tissue that predict survival time and potential new treatments for patients with non-small cell lung cancer.

15 Dec 2010

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced the results of two separate analyses at national medical conferences.

14 Dec 2010

Lilly suspends tasisulam global Phase III study in metastatic melanoma

Eli Lilly and Company announced today that it has suspended its global Phase III study evaluating tasisulam, an investigational, small-molecule anti-cancer compound, as a second-line treatment for those with unresectable or metastatic melanoma.

13 Dec 2010

Cancer researchers identify six gene markers in early stage NSCLC

Cancer researchers have identified six gene markers present in early stage non-small cell lung cancer (NSCLC) that show promise in helping oncologists better identify which tumors will relapse after curative surgery, according to a study presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology.